Table 1.
Analysis study population patient characteristics by duration of ART.
| Duration of combination ART
|
Excluded Population3 (n=998) | ||||||
|---|---|---|---|---|---|---|---|
| Factor | Level | 1 year (n=2073) | 3 years (n=1667) | 5 years (n=1267) | 10 years (n=638) | P2 | |
| Age at ART initiation (years) | <30 | 241 (12) | 172 (10) | 130 (10) | 65 (10) | 0.94 | 136 (13) |
| 30 to 39 | 801 (39) | 664 (40) | 497 (39) | 242 (38) | 396 (40) | ||
| 40 to 50 | 631 (30) | 510 (31) | 394 (31) | 206 (32) | 316 (32) | ||
| >50 | 400 (19) | 321 (19) | 246 (19) | 125 (20) | 150 (15) | ||
|
| |||||||
| Sex | Male/Transgender | 1955 (94) | 1573 (94) | 1191 (94) | 602 (94) | 0.98 | 936 (94) |
| Female | 118 (6) | 94 (6) | 76 (6) | 36 (6) | 62 (6) | ||
|
| |||||||
| Mode of Exposure | MSM | 1572 (76) | 1268 (76) | 963 (76) | 502 (79) | 0.93 | 715 (72) |
| Heterosexual | 201 (10) | 154 (9) | 116 (9) | 44 (7) | 102 (10) | ||
| Injecting drug use | 107 (5) | 81 (5) | 64 (5) | 33 (5) | 68 (7) | ||
| Blood Products/Other | 176 (8) | 147 (9) | 113 (9) | 53 (8) | 101 (10) | ||
| Unknown | 17 (1) | 17 (1) | 11 (1) | 6 (1) | 12 (1) | ||
|
| |||||||
| Patient care setting | General Practice | 748 (36) | 579 (35) | 424 (33) | 184 (29) | <0.01 | 402 (40) |
| Hospital | 586 (28) | 486 (29) | 391 (31) | 232 (36) | 144 (15) | ||
| Sexual Health Clinic | 739 (36) | 602 (36) | 452 (36) | 222 (35) | 452 (45) | ||
|
| |||||||
| Hepatitis B (HBsAg) | Yes | 89 (4) | 77 (5) | 56 (4) | 29 (5) | 0.97 | 52 (5) |
| No | 1703 (82) | 1388 (83) | 1086 (86) | 567 (89) | 774 (78) | ||
| Not reported | 281 (14) | 202 (12) | 125 (10) | 42 (7) | 172 (17) | ||
|
| |||||||
| Hepatitis C (HCV-antibody) | Yes | 223 (11) | 178 (11) | 144 (11) | 77 (12) | 0.75 | 115 (12) |
| No | 1668 (80) | 1352 (81) | 1043 (82) | 529 (83) | 758 (76) | ||
| Not reported | 182 (9) | 137 (8) | 80 (6) | 32 (5) | 125 (13) | ||
|
| |||||||
| PreART AIDS illness | Yes | 343 (17) | 288 (17) | 230 (18) | 135 (21) | 0.06 | 142 (14) |
| No | 1730 (83) | 1379 (83) | 1037 (82) | 503 (79) | 856 (86) | ||
|
| |||||||
| Prior ARV exposure at ART start | Yes | 549 (26) | 499 (30) | 432 (34) | 261 (41) | <0.01 | 455 (46) |
| No | 1524 (74) | 1168 (70) | 835 (66) | 377 (59) | 543 (54) | ||
|
| |||||||
| Year of ART start | 1996–2001 | 1394 (67) | 1242 (75) | 1040 (82) | 636 (100) | <0.01 | 648 (65) |
| 2001–2005 | 281 (14) | 243 (15) | 188 (15) | 2 (0) | 85 (9) | ||
| 2006–2012 | 398 (19) | 182 (10) | 39 (3) | 0 | 265 (26) | ||
|
| |||||||
| ART anchor agent1 | NNRTI | 850 (41) | 614 (37) | 406 (32) | 153 (24) | <0.01 | 399 (40) |
| PI | 993 (48) | 874 (52) | 712 (56) | 428 (67) | 440 (44) | ||
| II/Other | 230 (11) | 179 (11) | 149 (12) | 57 (9) | 159 (16) | ||
|
| |||||||
| CD4 cell count at ART initiation (cells/μL) | 0 to 200 | 629 (30) | 534 (32) | 405 (32) | 208 (33) | 0.90 | 149 (32) |
| 201 to 350 | 556 (27) | 429 (26) | 334 (26) | 164 (26) | 133 (28) | ||
| 351 to 500 | 430 (21) | 332 (20) | 256 (20) | 139 (22) | 100 (21) | ||
| >500 | 458 (22) | 372 (22) | 272 (22) | 127 (20) | 89 (19) | ||
|
| |||||||
| pVL at ART initiation (copies/ml) | 0–104 | 927 (45) | 719 (43) | 533 (42) | 288 (45) | 0.47 | 317 (56) |
| 104–105 | 635 (31) | 512 (31) | 384 (30) | 180 (28) | 134 (24) | ||
| >105 | 511 (25) | 436 (26) | 350 (28) | 170 (27) | 114 (20) | ||
|
| |||||||
| Number of ART regimen changes | mean | 0.8 | 2.1 | 3.3 | 6.1 | <0.01 | - |
| median(q1-q3) | 0(0–1) | 1(0–3) | 2(1–5) | 5(3–8) | |||
|
| |||||||
| Percentage of time | mean | 4.5 | 7.1 | 9 | 9.6 | <0.01 | - |
| ART interruption (%) | median(q1-q3) | 0.0(0.0–0.0) | 0.0(0.0–1.3) | 0.0(0.0–7.0) | 0.8(0.0–13.3) | ||
1
Initial ART regimen was classified as 2 N(t)RTI’s + (NNRTI or PI or Other); N(t)RTI – nucleos(t)ide reverse transcriptase inhibitors; NNRTI – non-nucleoside reverse transcriptase inhibitors; PI – protease inhibitors.
2
Categorical Factors: Chi-Squared Test, Continuous Factors: Analysis of Variance
3
AHOD participants who initiated ART who were excluded from the analysis due to (i) time on ART <6 months, (ii) missing CD4/pVL measurement at ART initiation, (iii) missing CD4/pvL measurement 24 weeks of ART, and (iv) less than 3 CD4/pVL measurements following post 24 weeks of ART.